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Sixteen new lung function signals identiﬁed through
1000 Genomes Project reference panel imputation
Marı´a Soler Artigas et al.#
Lung function measures are used in the diagnosis of chronic obstructive pulmonary disease.
In 38,199 European ancestry individuals, we studied genome-wide association of forced
expiratory volume in 1 s (FEV1), forced vital capacity (FVC) and FEV1/FVC with 1000
Genomes Project (phase 1)-imputed genotypes and followed up top associations in 54,550
Europeans. We identify 14 novel loci (Po5 10 8) in or near ENSA, RNU5F-1, KCNS3,
AK097794, ASTN2, LHX3, CCDC91, TBX3, TRIP11, RIN3, TEKT5, LTBP4,MN1 and AP1S2, and two
novel signals at known loci NPNT and GPR126, providing a basis for new understanding of the
genetic determinants of these traits and pulmonary diseases in which they are altered.
DOI: 10.1038/ncomms9658 OPEN
Correspondence and requests for materials should be addressed to I.P.H. (email: Ian.Hall@nottingham.ac.uk) or to M.D.T. (email: mt47@leicester.ac.uk).
#A full list of authors and their afﬁliations appears at the end of the paper.
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L
ung function, as measured by spirometry, predicts morbidity
and mortality1,2. Altered lung function is a key criterion for
the diagnosis of chronic obstructive pulmonary disease
(COPD), a leading cause of death worldwide3,4. The ratio of
forced expiratory volume in 1 s (FEV1) over forced vital capacity
(FVC) deﬁnes patients with airﬂow obstruction, while FEV1 is
used to assess the severity of the obstruction. Reduced FVC values
are seen in restrictive lung diseases such as pulmonary ﬁbrosis5.
While environmental risk factors, such as tobacco smoking or air
pollution, play a signiﬁcant role in determining lung function6,7,
genetic factors are also important contributors, with estimates of
heritability ranging between 39 and 54% (refs 8,9).
Genome-wide association studies (GWAS) of around 2.5
million common (minor allele frequency (MAF)45%) single-
nucleotide polymorphisms (SNPs) in Europeans have identiﬁed
32 loci associated with lung function at genome-wide signiﬁcance
level (Po5 10 8)10–14. However, as for other complex
traits15,16, these loci only explain a limited proportion of the
heritability11,13. Among explanations for the ‘missing heritability’
are a large number of, as yet, undetected common variants
with modest effect sizes, in addition to low-frequency
(1%oMAFr5%) and rare (MAFr1%) variants with larger
effect sizes16,17. Of particular relevance to low-frequency variants,
phase 1 of the 1000 Genomes Project18 sequenced 1,092
individuals from 14 populations, providing an imputation
reference panel of B38 million SNPs and 1.4 million indels,
including autosomal and X chromosome variants.
The aim of the current study, undertaken within the SpiroMeta
consortium, was to improve coverage of low-frequency variants
and detect novel loci associated with lung function by under-
taking imputation of GWAS data to the 1000 Genomes Project18
Phase-1 reference panel in 38,199 individuals of European
ancestry. We meta-analysed GWAS results across 17 studies
and followed up the most signiﬁcant associations with in silico
data in up to 54,550 Europeans. We identify 14 new loci
associated with lung function at genome-wide signiﬁcance level,
and novel distinct signals at two previously reported loci. These
include two low-frequency variant association signals, which
seem to be explained by non-synonymous SNPs. The results of
these analyses implicate both previously considered and novel
mechanisms inﬂuencing lung function.
Results
We undertook a meta-analysis of 17 GWAS imputed using the
1000 Genomes Project18 Phase-1 reference panel in a study of
38,199 individuals of European ancestry in stage 1 (Fig. 1), of
which 19,532 were individuals not included in the discovery stage
of previous meta-analyses of lung GWAS10–13. Characteristics of
cohort participants, genotyping and imputation are shown in
Supplementary Table 1. Each study adjusted FEV1, FEV1/FVC
and FVC, for age, age2, sex, height and principal components for
population structure, separately for never and ever smokers.
Fourteen studies additionally undertook analyses for X
chromosome variants (33,009 individuals, Supplementary Fig. 1
and Methods). Inverse normally transformed residuals were then
used for association testing within each smoking stratum,
assuming an additive genetic effect. Within each study, we
combined smoking strata association summary statistics using
inverse variance-weighted ﬁxed-effects meta-analysis, and applied
genomic control19 to account for residual population structure
not accounted for by principal components. We subsequently
combined study-speciﬁc estimates across studies using inverse
variance weighing, and applied genomic control19 after ﬁxed-
effects meta-analysis. The genomic inﬂation factor across
autosomal variants was 1.03 for each of the three traits, and
across X chromosome variants was 1.04 for FEV1 and 1.00 for
FEV1/FVC and FVC. Quantile–quantile plots are presented in
Supplementary Fig. 2a. Variants with effective sample sizes (N
effective, product of sample size and imputation quality summed
across studies) o70% were ﬁltered out, and a total of 8,694,268
variants were included in this genome-wide study.
Forty-eight SNPs and seven indels in independent autosomal
chromosome regions (±500 kb either side of sentinel variant)
with stage 1 Po5 10 6 were followed up in stage 2 using in
silico data from four studies comprising 54,550 individuals (Fig. 1;
Supplementary Table 2). One SNP on the X chromosome also
met these criteria and was followed up in a subset of three studies
comprising 52,359 individuals (Supplementary Fig. 1;
Supplementary Table 2). Characteristics of follow-up (stage 2)
cohort participants, genotyping and imputation are shown in
Supplementary Table 1. Stage-2 studies adjusted the traits for age,
age2, sex, height and principal components to account for
population structure and ever-smoking status, and also undertook
association testing on the inverse normally transformed residuals
assuming additive genetic effects. Stage-2 estimates were
combined across studies, and then with stage-1 estimates, using
inverse variance-weighted ﬁxed-effects meta-analysis. Thirteen
SNPs and three indels, each representing new signals of
association, met a genome-wide signiﬁcance threshold corrected
for multiple testing (Po5 10 8) after combining stage-1 and
stage-2 results (Table 1; Fig. 2), of which 10 SNPs and three indels
achieved independent replication meeting a Bonferroni-corrected
threshold for 56 tests (Po8.93 10 4) in stage 2 alone.
Sixteen novel association signals for FEV1, FEV1/FVC and FVC.
Of the 16 novel signals reaching genome-wide signiﬁcance, two
represent distinct new signals for FEV1/FVC in previously reported
loci10,12 (stage-1 P value conditioned on previously reported
varianto5 10 6). Among the remaining 14, ﬁve new loci were
identiﬁed for FEV1, six new loci for FEV1/FVC and three new loci
for FVC (Table 1). The sentinel variants at the 16 loci were in or
near the following genes: MCL1-ENSA (1q21.3), LYPLAL1-
RNU5F-1 (1q41), KCNS3-NT5C1B (2p24.2), AK097794 (3q25.32),
NPNT (4q24), GPR126-LOC153910 (6q24.1), ASTN2 (9q33.1),
LHX3 (9q33.1), PTHLH-CCDC91 (12p11.22), TBX3 (12q24.21),
TRIP11 (14q32.12), RIN3 (14q32.12), EMP2-TEKT5 (16p13.13),
STAGE 2 (follow-up studies) 
n=54,550
B58C (n=5,934)
BHS1&2 (n=4,355)
CROATIA-Korcula (n=826)
CROATIA-Split (n=493)
CROATIA-Vis (n=925)
EPIC population based (n=2,339)
GS:SFHS (n=8,093)
H2000 (n=821)
KORA F4 (n=1,474)
KORA S3 (n=1,147)
LBC1936 (n=991)
NFBC1966 (n=4,563)
NSPHS (n=871)
ORCADES (n=1,802) 
SAPALDIA (n=1,378)
SHIP (n=1,768) 
YFS (n=419)
ECRHS (n=1,747)
PIVUS (n=837)
TwinsUK (n=3,023) 
UK BiLEVE (n=48,943)
STAGE 1 (genome-wide association studies)
n=38,199
Figure 1 | Study design for autosomal chromosome analyses. The
discovery stage (stage 1) included 17 studies and 38,199 individuals. Fifty-
ﬁve variants were followed up in stage 2, which comprised four studies and
54,550 individuals.
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LTBP4 (19q13.2), MIAT-MN1 (22q12.1) and on chromosome X,
AP1S2-GRPR (Xp22.2) (Supplementary Fig. 2b,c). To gain further
insight into the associated variants, we assessed whether the novel
sentinel variants, or their proxies, were associated with gene
expression in lung tissues20 and blood21 (Methods, Supplementary
Methods; Supplementary Table 3a) or were in DNase
hypersensitivity sites22 in relevant cell types (Methods;
Supplementary Table 3b). For relevant genes, we investigated
RNA-seq splice isoforms in human bronchial epithelial cells
(Supplementary Methods; Supplementary Fig. 3), searched for
evidence of protein expression in the respiratory system23
(Supplementary Table 3c), assessed differential expression across
the pseudoglandular and canalicular stages of fetal human lung
development (Methods; Supplementary Table 3d) and assessed
evidence for differences in gene expression in bronchial epithelial
brush samples from COPD cases and smoking controls (Methods;
Supplementary Table 3e).
The two novel signals in known loci were the strongest
(Po5 10 23) association signals after meta-analysing
stage 1 and 2. The strongest signal was for a low-frequency
SNP near GPR126 (rs148274477, MAF¼ 2.4%, intergenic on
chromosome 6) associated with FEV1/FVC (P¼ 9.6 10 26,
Table 1) and in high linkage disequilibrium (LD, r2¼ 0.85) with a
missense variant (rs17280293 (Ser123Gly), Supplementary
Table 3f) in GPR126, but distinct from the previously reported
signal for FEV1/FVC in this region10,13 (stage-1 P value for
rs148274477 conditioning on rs3817928 (ref. 10) and rs262129
(ref. 13)¼ 1.86 10 7, unconditional stage-1 P¼ 2.68 10 9).
GPR126 encodes a G-protein-coupled receptor and is expressed
in adult and fetal lung tissue24,25 (Supplementary Table 3d).
Other studies have shown that GPR126 is required for mice
embryonic viability and cardiovascular development26, and that
GPR126 is expressed in adult mice lung27. More recently, GPR126
has been shown to bind type-IV collagen, a major collagen in the
lung, leading to cAMP signalling28.
The second strongest signal (P¼ 1.5 10 23, Table 1) was an
intronic SNP (rs6856422) in NPNT on chromosome 4 associated
with FEV1/FVC, distinct from the previously discovered signal for
Table 1 | Variants associated with FEV1, FEV1/FVC or FVC.
rs number
(chr:position)
Gene (function) eQTL
gene
Coded
allele/
other
allele
Measure Stage 1 Stage 2 Meta-analysis
Coded
allele
freq.
N Beta
(s.e.)
P Coded
allele
freq.
N Beta (s.e.) P Beta (s.e.) P
rs6681426
(chr1:150586971)
MCL1
(dist.¼ 34,757),
ENSA
(dist.¼ 7,628)
ARNT G/A FEV1 0.36 37,944 0.042
(0.008)
1.07 10 7 0.35 5,4301 0.021
(0.006)
1.13 10 3 0.029
(0.005)
4.35 109
rs201204531
(chr1:219963090)
LYPLAL1
(dist.¼ 576,883),
RNU5F-1
(dist.¼ 83,529)
— A/ATG FEV1/FVC 0.41 34,866 0.038
(0.008)
1.98 106 0.38 53,760 0.027
(0.006)
1.77 10 5 0.031
(0.005)
2.68 10 10
rs61067109
(chr2:18292452)
KCNS3
(dist.¼ 178,227),
NT5C1B
(dist.¼443,537)
— G/A FEV1/FVC 0.77 37,416 0.050
(0.009)
3.09 108 0.77 54,341 0.042
(0.007)
6.56 109 0.045
(0.006)
1.40 10 15
rs6441207
(chr3:158282459)
AK097794
(ncRNA_intronic)
MLF1 C/T FVC 0.59 36,173 0.036
(0.008)
4.54 106 0.59 53,174 0.036
(0.006)
5.85 109 0.036
(0.005)
1.27 10 13
rs6856422
(chr4:106841962)
NPNT (intronic) — G/T FEV1/FVC 0.53 31,446 0.044
(0.008)
1.30 10 7 0.56 49,026 0.055
(0.006)
1.15 10 17 0.051
(0.005)
1.51 10 23
rs148274477
(chr6:142838173)
GPR126
(dist.¼ 70,770),
LOC153910
(dist.¼ 9,419)
— C/T FEV1/FVC 0.98 30,398 0.161
(0.027)
2.68 109 0.97 50,047 0.162
(0.019)
5.63 10 18 0.162
(0.015)
9.58 10 26
rs34886460
(chr9:119359372)
ASTN2 (intronic) — T/TA FEV1/FVC 0.53 37,567 0.041
(0.008)
6.75 108 0.54 53,920 0.025
(0.006)
4.07 10 5 0.031
(0.005)
4.72 10 11
rs2274116
(chr9:139094805)
LHX3 (exonic) QSOX2 C/T FVC 0.67 32,004 0.041
(0.009)
2.68 106 0.66 51,730 0.038
(0.007)
4.20 109 0.039
(0.005)
5.55 10 14
rs11383346
(chr12:28283187)
PTHLH
(dist.¼ 158,271),
CCDC91
(dist.¼ 126,946)
CCDC91 A/AT FVC 0.41 37,254 0.043
(0.008)
3.83 108 0.41 53,931 0.041
(0.006)
4.42 10 11 0.042
(0.005)
9.52 10 18
rs10850377
(chr12:115201436)
TBX3
(dist.¼ 79,467),
MED13L
(dist.¼ 1,194,945)
— G/A FEV1 0.67 37,268 0.047
(0.008)
6.68 109 0.65 52,722 0.028
(0.006)
1.55 10 5 0.035
(0.005)
2.50 10 12
rs7155279
(chr14:92485881)
TRIP11 (intronic) ATXN3 G/T FEV1 0.64 37,691 0.041
(0.008)
1.39 10 7 0.64 54,471 0.022
(0.006)
4.17 104 0.030
(0.005)
1.41 109
rs117068593
(chr14:93118229)
RIN3 (exonic) — C/T FEV1 0.82 34,496 0.048
(0.010)
2.72 106 0.81 52,572 0.027
(0.008)
5.68 104 0.035
(0.006)
2.25 108
rs12149828
(chr16:10706328)
EMP2
(dist.¼ 31,789),
TEKT5
(dist.¼ 15,033)
— G/A FEV1/FVC 0.83 33,999 0.049
(0.010)
3.16 106 0.83 50,807 0.035
(0.008)
3.33 10 5 0.040
(0.007)
7.65 10 10
rs113473882
(chr19:41124155)
LTBP4 (intronic) — T/C FEV1/FVC 0.98 32,207 0.174
(0.033)
1.48 10 7 0.99 52,907 0.138
(0.028)
1.00 106 0.153
(0.021)
9.95 10 13
rs134041
(chr22:28056338)
MIAT
(dist.¼ 983,898),
MN1
(dist.¼ 87,927)
— T/C FEV1 0.43 37,669 0.045
(0.008)
4.19 10 9 0.44 52,770 0.018
(0.006)
4.19 10 3 0.028
(0.005)
3.03 109
rs7050036
(chrX:15964845)
AP1S2
(dist.¼ 91,708),
GRPR
(dist.¼ 176,579)
— T/A FEV1/FVC 0.38 32,285 0.041
(0.007)
4.37 109 0.39 50,530 0.013
(0.005)
1.60 10 2 0.023
(0.004)
4.14 108
Chr., chromosome; dist., distance; eQTL, expression quantitative trait loci; FDR, false discovery rate; FEV1, forced expiratory volume in 1 s; freq., frequency; FVC, forced vital capacity.
Results are shown for each sentinel variant associated (Po5 108) with FEV1, FEV1/FVC or FVC in a joint analysis of up to 92,744 individuals of European ancestry, ordered by chromosome and
position. The allele frequency presented in the table corresponds to the coded allele (Coded allele freq.), which was chosen as the reference allele in the 1000 Genomes Project reference panel, and in
most instances (but not always) is the major allele. Two-sided P values are given for stage 1, stage 2 and the meta-analysis of both stages. Variants reaching independent replication in stage 2 (P¼0.05/
56¼8.93 104) are indicated with their stage-2 P value in bold. The sample sizes (N) shown are the effective sample sizes. The effective sample size within each study is the product of sample size
and the imputation quality metric. Beta values reﬂect effect-size estimates on an inverse-normal transformed scale after adjustments for age, age2, sex, height and ancestry principal components, and
stratiﬁed by ever-smoking status. ‘eQTL gene’ presents a gene expressed in the lung, whose expression is associated with the highest ranking proxy for the sentinel variant (ranking on r2 with sentinel
ﬁrst, all with r240.8, and on eQTL P-value second, all with Po5 10 5) with FDR o10%.
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FEV1 in this region10,12,13. The stage-1 P value for this variant
conditioned on the previously reported sentinel SNPs (rs17036341
(ref. 10) and rs10516526 (refs 12,13)) and on the sentinel SNP for
FEV1 in this analysis (rs12374256, INTS12 intron) was 4.7 10 6
(unconditional stage-1 P¼ 1.30 10 7). Proxies of the sentinel
SNP were associated with expression of INTS12 and GSTCD in
blood (Supplementary Table 3a). INTS12, GSTCD and NPNT are
contiguously positioned at 4q24, and are all expressed in adult and
fetal lung tissues (Supplementary Table 3c,d). Our previous work
characterizing GSTCD and INTS12 showed that they are oppositely
transcribed genes that are to some extent co-ordinately regulated,
although while GSTCD expression in human lung tissue is
ubiquitous, INTS12 expression was predominantly in the nucleus
of epithelial cells and pneumocytes29.
Among the 14 novel loci, six novel loci were associated with
FEV1/FVC. One of them was a low-frequency variant
(rs113473882, intronic in LTBP4 on chromosome 19,
MAF¼ 1.5%, Table 1) in almost complete LD (r2¼ 0.99) with a
missense variant (rs34093919, Asp752Asn, Supplementary
Table 3f) in LTBP4, which encodes a protein that binds
transforming growth factor beta (TGFb) as it is secreted and
targeted to the extracellular matrix. Mice deﬁcient in ltbp4
displayed defects in lung septation and elastogenesis, which may
be TGFb2 and ﬁbulin-5 dependent30, and disruption of this gene
in mice led to abnormal lung development, cardiomyopathy and
colorectal cancer31. Variants near LTBP4, uncorrelated (r2o0.05)
with the sentinel SNP we report here, have been associated with
COPD32 and smoking behaviour33. A further novel FEV1/FVC
locus mapping near AP1S2 is the ﬁrst to be reported for lung
function on the X chromosome; sentinel SNP (rs7050036,
intergenic) proxies were associated with the expression of
AP1S2 and ZRSR2 in lung tissue (Supplementary Table 3a).
Other new loci for FEV1/FVC were in or near KCNS3 (2p24.2),
ASTN2 (9q33.1), RNU5F-1 (1q41) and TEKT5 (16p13.13).
The strongest signal for FEV1 in a novel locus was upstream of
TBX3 on chromosome 12 (Table 1); TBX3 is involved in the
TGFb1 signalling pathway34. At a second novel locus for FEV1
(rs7155279, TRIP11 intron on chromosome 14, Table 1), proxies
of the sentinel variant were associated with lung and blood
expression of TRIP11. TRIP11 encodes a protein associated with
the Golgi apparatus35. In the lung, rs7155279 showed strongest
association with expression of ATXN3 (Supplementary Table 3a),
which encodes ataxin 3, a deubiquitinating enzyme. Expanded
trinucleotide repeats in ATXN3 cause spinocerebellar ataxia-3
(ref. 36). In blood, a proxy (r2¼ 0.94) for rs7155279 showed
strong association (P¼ 3 10 34, Supplementary Table 3a) with
the expression of FBLN5. Fibulin-5 was shown to be implicated in
tissue repair in COPD37 and elastogenesis and lung
development30. A third signal for FEV1 was a missense variant
(rs117068593, Arg279Cys, Supplementary Table 3f) in RIN3 on
Chromosome
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Figure 2 | Manhattan plots for association results. (a) FEV1, (b) FEV1/FVC and (c) FVC. Manhattan plots ordered by chromosome and position for stage-
1 results. Variants with Po5 106 are indicated in red. Novel signals that reached genome-wide signiﬁcance after meta-analysing stage 1 and stage 2 are
labelled with the nearest gene. Only variants with N effective Z70% are presented here.
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chromosome 14 (Table 1), which was B632 kb from the TRIP11
sentinel SNP (rs7155279) and independent from it
(r2¼ 8.84 10 5). Although this is the ﬁrst report of association
of a RIN3 variant with lung function, a correlated variant (rs754388,
r2¼ 0.99) was recently associated with moderate to severe COPD,
although the association did not replicate in an independent
study38. In a fourth novel region for FEV1, on chromosome 1, a
sentinel SNP, rs6681426, B8 kb downstream of ENSA (Table 1)
and a second signal B700kb apart (rs4926386, Supplementary
Table 2a) were both associated with ARNT expression in lung
(Supplementary Table 3a). ARNT is differentially expressed during
fetal lung development (Supplementary Table 3d) and acts as a co-
factor for transcriptional regulation by hypoxia-inducible factor 1
during lung development39 and may regulate cytokine responses40.
SNP rs6681426 was also associated with the expression of LASS2
(also known as CERS2) in lung tissue (Supplementary Table 3a);
lass2 knock-out mice develop lung inﬂammation and airway
obstruction41. The other new locus for FEV1 was near MN1
(22q12.1).
All three novel loci for FVC had sentinel variants or close
proxies associated with expression of a nearby gene in lung,
implicating CCDC91, MLF1 and QSOX2, located on chromo-
somes 12, 3 and 9, respectively. The putative function of the key
genes in each of the two known and 14 novel loci for FEV1, FEV1/
FVC and FVC are summarized in Supplementary Table 4.
Functional characterization of novel signals. The protein pro-
ducts of genes nearest to the sentinel variant of novel signals for
lung function were expressed in bronchial epithelial cells, pneu-
mocytes or lung macrophages (Supplementary Table 3c). Among
the 16 novel signals of association with lung function, sentinel
variants or close proxies were cis expression quantitative trait loci
(eQTLs) in lung for ARNT, MLF1, QSOX2, CCDC91 and ATXN3
(Table 1; Supplementary Table 3a), and in eight loci the sentinel
variant or at least one strong proxy (r240.8) was in a DNase
hypersensitivity site in a cell type potentially relevant to lung
function (in or near ENSA, RNU5F-1, ASTN2, CCDC91, TBX3,
RIN3, TEKT5 and MN1, Supplementary Table 3b). The sentinel
variant association was explained (conditional P40.01) by a mis-
sense variant in each of the two novel signals in which we detected
a low-frequency sentinel variant (near GPR126 and in LTBP4), and
was explained in four of the remaining novel signals by a putatively
functional variant (in or near ENSA, AK097794, TEKT5 and MN1,
Supplementary Table 3f and Methods). Genes in four of the novel
loci showed differential expression across the pseudoglandular and
canalicular stages of fetal lung development, particularly EMP2
(Supplementary Table 3d). MLF1 and ATXN3 showed differences
in expression levels in bronchial brushings between COPD cases
and controls (Supplementary Table 3e). We detected novel splice
isoforms of 420% abundance for GFM1, TRIM32, LTBP4 and
MN1 in human bronchial epithelial cells (Supplementary Fig. 3;
Supplementary Methods).
Association in children. To assess whether the 16 new sentinel
variants associated with lung, function in adults may act through
an effect on lung development, we assessed their association in
the ALSPAC study42 that includes 5,062 children (Supplementary
Table 5a). Eleven of the 16 sentinel variants showed consistent
directions of effect in adults and children. The association with
FVC of variant rs6441207 on chromosome 3 in the noncoding
RNA AK097794 exceeded a Bonferroni-corrected threshold for 16
tests (Supplementary Table 5a).
Association with smoking and gene by smoking interaction.
The 16 new variants had consistent effect sizes in never smokers
and ever smokers, and no gene–smoking interaction (P40.05) in
stage 1 (Supplementary Table 5b). We found no evidence that any
of these signals were driven by smoking behaviour. Only the two-
base-pair insertion on chromosome 1 (rs201204531) revealed an
association (P¼ 1.5 10 3) with smoking behaviour (heavy-
versus never-smoking status) that met a Bonferroni-corrected
threshold for 16 tests (Supplementary Table 5c). However, this
variant also showed an association with FEV1/FVC in never
smokers, and the allele associated with higher likelihood
of being a smoker was associated with increased FEV1/FVC
(Supplementary Table 5b,c).
Associations with other traits. We queried the GWAS catalog43
for variants in 2-Mb regions centred on the sentinel variant for
the 16 loci (Supplementary Table 5d). Five loci contained variants
associated with height44–46 (Supplementary Table 5d). In the
GPR126 and LHX3 loci, the previously reported height variants
were not correlated (r2o0.2) with the lung function variants
reported here. In the AK097794, CCDC91 and TRIP11 loci, the
variants associated with height were correlated (r240.3) with the
lung function sentinel variants, but the alleles associated with
reduced height were associated with increased FEV1 or FVC.
Associations with other traits have been reported for variants in
LD (r240.3) with sentinel variants in regions of RIN3 (Paget’s
disease47 and bone mineral density48), ENSA (body fat mass49
and melanoma50) and LHX3 (thyroid hormone levels51). None of
the novel signals relate to known asthma loci, and the association
ﬁndings were consistent after removing individuals with asthma
(Supplementary Fig. 4).
Genetic architecture of lung function traits. The proportion of
the additive polygenic variance explained by the 49 signals dis-
covered to date (Supplementary Table 6), including new and
previously reported signals10–14 is 4.0% for FEV1, 5.4% for FEV1/
FVC and 3.20% for FVC (Supplementary Table 7). These
estimates are likely upper bounds on the proportion of the
variance explained due to the winner’s curse bias. Across the 49
signals, we observed larger effect sizes for associations with lower-
frequency variants (Fig. 3), supporting the hypothesis that lower-
frequency variants will contribute to explaining the missing
heritability16.
We examined the increase in coverage of low-frequency and
common variants by the 1000 Genomes Project reference panel,
compared with the HapMap imputation reference panel, at both
the novel and previously reported loci (Supplementary Fig. 5a).
The two association signals where the 1000 Genomes sentinel
variants had low MAF (o5%), were not present when restricting
the results only to variants that could be imputed using the
HapMap imputation panel (rs113473882 and rs148274477 in
Supplementary Fig. 5a).
For each of the 32 previously discovered regions10–14, we
identiﬁed the most strongly associated variant present on the
1000 Genomes Project18 reference panel and the most strongly
associated variant present on the HapMap reference panel using
stage-1 results, and compared the stage-1 MAFs between these
two groups of variants. The 1000 Genomes sentinel variants in or
near GPR126 (rs148274477), TGFB2 (rs147187942) and MMP15
(rs150232756) had MAFs that were more than twofold lower than
the HapMap sentinel variant MAFs (Supplementary Fig. 5b) and
were statistically independent (r2r0.06) from the previously
discovered HapMap-imputed sentinel variants13. The GPR126
1000 Genomes-imputed sentinel was described above as one of
the 16 new signals. We tested the association of the 1000
Genomes-imputed sentinel variants near TGFB2 and MMP15 in
UK BiLEVE (Supplementary Table 8), and found supportive
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evidence of association for the signal near TGFB2 (rs147187942,
MAF¼ 9%, P¼ 5.7 10 3).
Pathway analyses. We undertook a pathway analysis using
MAGENTA v2 (ref. 52) and stage-1 genome-wide results for FEV1,
FEV1/FVC and FVC (Supplementary Methods). For
FVC, the platelet-derived growth factor signalling, and the
chromatin-packaging and -remodelling pathways were signi-
ﬁcant (P¼ 2 10 4, false discovery rate (FDR)o0.3% and
P¼ 1.82 10 4, FDRo4%, respectively) (Supplementary Table 9).
Discussion
In this study, we aimed to improve coverage of low-frequency
variants and detect novel loci associated with lung function, by
undertaking imputation of GWAS data in 17 studies and 38,199
individuals to the 1000 Genomes Project18 reference panel, and
by following up the most signiﬁcant signals in an additional
54,550 individuals. Overall, 16 new association signals attained a
genome-wide signiﬁcance threshold corrected for multiple testing
(Po5 10 8) after meta-analysing stage 1 and stage 2, including
15 autosomal and one X chromosome signal. While two of the
new ﬁndings relate to novel signals for FEV1/FVC in previously
reported regions10,12, ﬁve new loci were identiﬁed for FEV1, six
new loci for FEV1/FVC and three new loci for FVC. Including the
16 signals discovered in these analyses, the number of lung
function signals discovered to date is 49 (refs 10–14), and they
jointly explain a modest proportion of the additive polygenic
variance (4.0% for FEV1, 5.4% for FEV1/FVC and 3.2% for FVC).
Some of the 49 distinct lung function signals10–14 seem to
cluster close to each other. If we deﬁne regions as 500 kb either
side of the sentinel variants, there are three regions that each
include two distinct signals (in or near INTS12-GSTCD-NPNT,
GPR126 and PTCH1 (refs 10,12)), so that the 49 signals would
map to 46 loci. If we use a wider deﬁnition of region (1,000 kb
either side of the sentinel), there are four regions that each
include two distinct signals (in or near INTS12-GSTCD-NPNT,
GPR126, PTCH1 (refs 10,12) and TRIP11-RIN3). In addition, the
human leukocyte antigen region on chromosome 6 includes three
distinct signals (in or near ZKSCAN3-NCR3-AGER10,12,13)
within 3.8Mb. Furthermore, we have shown evidence of an
additional signal in the TGFB2 region, and the new lung function
signal in LTBP4 lies 179 kb away from a known COPD signal32.
These ﬁndings are consistent with reports from very large studies
of height and lipids53,54, which report multiple signals in
associated regions, and highlight the importance of taking into
account LD between variants to improve our understanding of
known regions. Multiple signals within known regions are likely
to explain some of the hidden heritability of these traits.
To identify pathways relevant to lung function, we undertook
additional analyses using MAGENTA, which have implicated
pathways for platelet-derived growth factor signalling and chroma-
tin-packaging and -remodelling. Independent analyses undertaken
in a concurrent study by the UK BiLEVE consortium, which focused
on the extremes of the lung function distribution55, highlight the
histone subset of the chromatin-packaging and -remodelling
pathway. The TGFb signalling pathway has now been implicated
by three independent loci: an FEV1/FVC signal explained by a
missense variant in LTBP4, which encodes a protein that binds
TGFb; an FEV1 signal upstream of TBX3, which is involved in the
TGFb1 signalling pathway34; and a previously reported signal
downstream of TGFB2 (ref. 17). In addition, a pathway involving
ﬁbulin-5 has been implicated by two of the novel loci (LTBP4 and
TRIP11). The identiﬁcation, through different approaches, of
pathways which appear to be involved in determining lung
function should help focus future functional studies.
Pathways affecting lung function also have the potential to
affect COPD risk, since lung function measures are used to
diagnose the disease. Currently, 13 signals (in or near TGFB2,
TNS1, RARB, FAM13A, GSTCD, HHIP, HTR4, ADAM19, AGER,
LOC153910, C10orf11, RIN3 and THSD4) out of the 49 lung
function signals discovered to date10–14 have also shown
association with some deﬁnition of COPD38,56–60. This
illustrates that the study of lung function measures is a
powerful approach to bring insights into the genetics of COPD.
In agreement with previous ﬁndings for other lung function
loci12,13, none of the 16 new associations seem to be driven by
either smoking behaviour or by a gene–smoking interaction. One
variant showed association with smoking behaviour that met a
Bonferroni correction for 16 tests in UK BiLEVE. This variant also
had an effect in never smokers in stage 1, and the allele associated
with increased lung function was also associated with increased risk
of smoking, which does not suggest an association with lung
function mediated by smoking behaviour. Variants in ﬁve out of the
16 loci associated with lung function in this study have also shown
associations with height44–46. However, the variants associated with
height were either independent of those associated with lung
function, or if they were correlated, the alleles associated with
increased height, were associated with decreased FEV1 or FVC. If
the association with lung function was driven by an effect on height,
we would expect consistent direction of effect between these two
traits. Therefore, the associations identiﬁed for lung function in
these regions are not likely to be driven by associations with height.
This study had a large follow-up stage, which included 54,550
individuals, of which 48,943 were contributed by the UK BiLEVE
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Figure 3 | Minor allele frequency against effect-size plots (a) FEV1, (b) FEV1/FVC and (c) FVC. MAF is plotted against stage-1 effect sizes for variants
within the 33 known10–14 and the 16 new signals, which had stage-1 Po0.05 for association with FEV1, FEV1/FVC and FVC separately. Known signals are
represented with blue circles and new signals are represented with orange triangles.
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study. UK BiLEVE is a particularly powerful study since it has
sampled UK Biobank individuals from the extremes of the lung
function distribution, and it has spirometry performed in a
uniform way across individuals. Had these data been available
when we undertook the discovery stage of this study, their
addition would have greatly improved the discovery power.
Nevertheless, incorporating these data into the follow-up stage
improved power to provide replication and deal with potential
winners’ curse bias. Another strength of the current study design
was the increased coverage of common and low-frequency
variants obtained through the imputation to 1000 Genomes
Project18 reference panel. This enabled us to detect two low-allele-
frequency variants (with MAF of 1.5 and 2.4% and stage-1 effect
sizes of 0.17 and 0.16 s.d. units, respectively) that have an effect on
lung function. No associations with lower allele frequency variants
have been detected in this study, despite having power 480% in
discovery to detect associations (Po5 10 6) for variants with
MAF of 0.5 and 1%, and effect sizes above 0.3 and 0.2 s.d. units,
respectively. The poorer imputation quality for low-allele-
frequency variants coupled with the strict criteria we used to
select variants for follow-up (N effective Z70%) have probably
affected our ability to detect rare variants. For instance, a variant
representing an additional signal for FEV1/FVC in the GSTCD-
INTS12-NPNT region, reported by the UK BiLEVE study, where it
was directly genotyped55, would have been detected in this
analysis had we used a more lenient threshold (N effective460%).
Imputation quality for rare variants will improve as larger
imputation reference panels become available.
In summary, 16 new association signals for lung function have
been identiﬁed in this study, including two signals explained by
non-synonymous low-frequency variants. These ﬁndings high-
light new loci not previously connected with lung function or
COPD, and bring new insights into previously detected loci. This
study also highlights the added value of imputing to new
reference panels as they become available. Understanding the
molecular pathways that connect the newly identiﬁed loci with
lung function and COPD risk has the potential to point to new
targets for therapeutic intervention.
Methods
Study design. The study consisted of two stages. Stage 1 was a meta-analysis of 17
GWAS in a total of 38,199 individuals of European ancestry. Supplementary
Table 1 gives the details of these studies. Fifty-six variants selected according to the
results in stage 1 were followed up in stage 2 in 54,550 European individuals.
Stage-1 samples. Stage 1 comprised 17 studies: B58C (T1DGC and WTCCC),
BHS1 and -2, EPIC (obese cases and population-based studies), the EUROSPAN
studies (CROATIA-Korcula, ORCADES, CROATIA-Split and CROATIA-Vis),
GS:SFHS, Health 2000, KORA F4, KORA S3, LBC1936, NFBC1966, NSPHS,
SAPALDIA, SHIP and YFS (see Supplementary Table 1a for the deﬁnitions of all
abbreviations). All participants provided written informed consent and studies
were approved by local Research Ethics Committees and/or Institutional Review
Boards. Measurements of spirometry for each study are described in the
Supplementary Note. The genotyping platforms and quality-control criteria
implemented by each study are described in Supplementary Table 1b.
Imputation. Imputation to the all ancestries 1000 Genomes Project18 Phase-1
reference panel released in March 2012 was undertaken using MACH61 and
minimac62 or IMPUTE2 (ref. 63) with pre-imputation ﬁlters and parameters as
shown in Supplementary Table 1b. Speciﬁc software guidelines were used to impute
the non-pseudoautosomal part of the X chromosome. The pseudoautosomal part
of the X chromosome was not included in these analyses. Variants were excluded if
the imputation information, assessed using r2.hat (MACH and minimac) or .info
(IMPUTE2), was o0.3.
Data transformation and association testing in stage 1. Linear regression of
age, age2, sex, height and principal components for population structure was
undertaken on FEV1, FEV1/FVC and FVC separately for ever smokers and never
smokers. The residuals were transformed to ranks and then transformed to nor-
mally distributed z-scores. These transformed residuals were then used as the
phenotype for association testing under an additive genetic model, separately for
ever smokers and never smokers. For X chromosome analyses, residuals for males
and females were analysed separately and dosages for males were coded 0 for 0
copies of the coded allele and 2 for 1 copy of the coded allele. The software used
was speciﬁed in Supplementary Table 1b. Studies with related individuals analysed
ever smokers and never smokers together adjusting the regression for ever-smoking
status and used appropriate tests for association in related individuals, as described
in the Supplementary Note.
Meta-analysis of stage-1 data. Quality-control checks on the stage-1 data were
undertaken using GWAtoolbox64 and R version 3.0.2 (see URLs). All meta-analysis
steps were undertaken using inverse variance-weighted ﬁxed-effects meta-analysis.
Effect estimates were ﬂipped across studies so that the coded allele was the reference
allele in the 1000 Genomes Project18 reference panel. For each study with unrelated
individuals, autosomal chromosomes results were meta-analysed between ever
smokers and never smokers. After that, all study-speciﬁc standard errors were
corrected using genomic control19. Study-speciﬁc genomic inﬂation factor estimates
are shown in Supplementary Table 1a. Finally, effect-size estimates and s.e. were
combined across studies, and genomic control19 was applied again at the meta-
analysis level. For the X chromosome, studies of unrelated individuals meta-analysed
smoking strata estimates within sex strata and then meta-analysed pooled sex strata
estimates. After that, genomic control19 was applied to each study and results were
meta-analysed across studies. Genomic control19 was applied again after the meta-
analysis. To describe the effect of imperfect imputation on power, for each variant we
report the effective sample size (N effective), which is the sum of the study-speciﬁc
products of the sample size and the imputation quality metric. Meta-analysis statistics
and ﬁgures were produced using R version 3.0.2 (see URLs).
Selection of variants for stage 2. Variants with N effective o70% were ﬁltered
out before selecting variants for follow-up (8,916,621 variants remained after
ﬁltering). Independent regions (±500 kb from the sentinel variant) were selected
for FEV1, FEV1/FVC and FVC if the sentinel SNP or indel had Po5 10 6. If the
same variant was selected for different traits, it was followed up for all the traits. If
two different variants were selected for different traits within the same region, or if
any of the regions selected had already been identiﬁed in previous GWAS10–14 but
the sentinel variant was different from that previously reported, conditional
analyses were undertaken to assess whether the signals within the same regions
were distinct. If previously reported sentinel SNPs for a region were strongly
correlated (r240.9), we only conditioned on the SNP that had shown the strongest
association. If two variants were selected for different traits within the same new
region, both variants were taken forward if their P-value conditioning on the other
variant was o5 10 6; if not, only the variant with the most signiﬁcant P value
was taken forward. Variants within known regions were only taken forward if their
P value conditioned on the previously reported variant was o5 10 6.
Conditional analyses were undertaken using GCTA65, and B58C data were used to
estimate LD. In total, 56 variants (49 SNPs and seven indels) were taken forward
for follow-up, two of which were distinct signals within previously reported
regions10,12,13. These variants are listed in Supplementary Table 2. Previously
reported signals10–14 were not followed up.
Stage-2 samples. The 48 SNPs and seven indels on autosomal chromosomes were
followed up in up to 54,550 individuals from four studies with in silico data:
ECRHS, PIVUS, TwinsUK and UK BiLEVE (see Supplementary Table 1a for the
deﬁnitions of all abbreviations). All participants provided written informed consent
and studies were approved by local Research Ethics Committees and/or Institu-
tional Review Boards. One SNP in the chromosome X was followed up in 52,359
individuals from PIVUS, TwinsUK and UK BiLEVE. Measurements of spirometry
for each study are described in the Supplementary Note.
Meta-analysis of stage-2 data. All stage-2 studies undertook linear regression of
age, age2, sex, height, ever-smoking status and principal components for popula-
tion structure, if available, on FEV1, FEV1/FVC and FVC, then the residuals were
transformed to ranks and to normally distributed Z-scores. These transformed
residuals were then used as the phenotype for association testing under an additive
genetic model. For the X chromosome analyses, allele dosages for hemizygous
males were coded as 2. Effect sizes were ﬂipped to be consistent with the stage-1
estimates, using the reference allele in 1000 Genomes Project18 as the coded allele.
Genomic control19 was applied for studies that undertook the analysis genome-
wide. Effect estimates and s.e. were combined across the stage-2 studies using an
inverse variance-weighted meta-analysis.
Combination of stage 1 and 2 and multiple testing correction. A meta-analysis
of stage-1 and stage-2 results was undertaken using inverse variance-weighted
meta-analysis. We take into account the multiple tests undertaken by describing an
association as genome-wide signiﬁcant if it has Po5 10 8. In addition, we
assessed whether any of the ﬁndings achieved independent replication in stage 2
using a threshold corrected for the number of variants followed up (0.05/
56¼ 8.93 10 4).
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Functional characterization of novel loci. A series of analyses were undertaken to
provide insights into the expression of genes within the 16 loci (deﬁned as ±1Mb
either side of the sentinel variant) represented here. Blood21 and lung tissue20 eQTL
analyses were undertaken for variants in these loci that were in LD (r240.3) with the
sentinel variant in the region. We assessed whether variants within these loci that
were strongly correlated with the sentinel variants (r240.8) were in DNase
hypersensitivity sites as deﬁned by ENCODE22 for cells potentially relevant to lung
function. We also carried out conditional analyses, using GCTA65, of sentinel
variants conditioning on functional variants within the loci to assess whether the
association signals were explained by functional variants (P value of the sentinel
variant conditioned on the functional variant, conditional P, 40.01). Functional
variants were deﬁned using SIFT66, PolyPhen-2 (ref. 67), CADD68 and GWAVA69
databases. Additional analyses were undertaken for a subset of priority genes within
the 16 loci (description of the selection is given in the Supplementary Methods).
These included RNA-seq analyses to conﬁrm messenger RNA expression in a lung-
relevant cell (bronchial epithelium) and detect novel splice isoforms; assessment of
differential expression across pseudoglandular and canalicular stages of human fetal
lung development using gestational age as a continuous variable in linear
regression25, and assessment of differences in expression levels in bronchial
brushings between COPD cases and smoking controls70. Details for all these analyses
are provided in the Supplementary Methods.
Associations with other traits. The association of the 16 sentinel variants with
the following traits was assessed: lung function in children undertaking the same
analysis as for adults in the ALSPAC data set42; gene by smoking interaction by
undertaking a Z-test comparing the effect of a given variant in ever smokers and in
never smokers using stage-1 results; smoking behaviour by undertaking a logistic
regression analysis with heavy- versus never-smoking status as an outcome in the
UK BiLEVE data set. In addition, the GWAS catalog43 was queried for variants in
2-Mb regions centred on the sentinel variant for the 16 loci. Variants that were
genome-wide signiﬁcant (Po5 10 8) in the GWAS catalog43 and were in LD
(r240.3) with the sentinel variants, or were in genes that contained at least one
variant in LD (r240.3) with the sentinel variants were selected.
Pathway analyses. Stage-1 GWAS results were tested for enrichment of known
biological pathways using MAGENTA v2 (ref. 52). Six databases of biological
pathways, including Ingenuity Pathway (June 2008, number of pathways n¼ 81),
KEGG (2010, n¼ 186), PANTHER Molecular Function (January 2010, n¼ 216),
PANTHER Biological Processes (January 2010, n¼ 217), PANTHER Pathways
(January 2010, n¼ 94) and Gene Ontology (April 2010, n¼ 1778), were tested. An
FDR threshold of 5% was used and signiﬁcance thresholds were Bonferroni
corrected for each database. Genes within 500 kb either side from the sentinel
variants were ﬂagged in the analysis. Sensitivity analyses were run after removing
genes in the human leukocyte antigen region on chromosome 6. More details on
the method are provided in the Supplementary Methods.
Additional analyses. Heterogeneity tests were undertaken for the 16 sentinel
variants in stage 1. We undertook stepwise conditional analyses as performed by
GCTA65 in each locus to identify additional signals. Full methods and results are
described in the Supplementary Notes.
References
1. Hole, D. J. et al. Impaired lung function and mortality risk in men and women:
ﬁndings from the Renfrew and Paisley prospective population study. BMJ 313,
711–715 discussion 715–716 (1996).
2. Young, R. P., Hopkins, R. & Eaton, T. E. Forced expiratory volume in one
second: not just a lung function test but a marker of premature death from all
causes. Eur. Respir. J. 30, 616–622 (2007).
3. Lopez, A. D. et al. Chronic obstructive pulmonary disease: current burden and
future projections. Eur. Respir. J. 27, 397–412 (2006).
4. Lozano, R. et al. Global and regional mortality from 235 causes of death for 20
age groups in 1990 and 2010: a systematic analysis for the Global Burden of
Disease Study 2010. Lancet 380, 2095–2128 (2012).
5. Zappala, C. J. et al. Marginal decline in forced vital capacity is associated with a
poor outcome in idiopathic pulmonary ﬁbrosis. Eur. Respir. J. 35, 830–836 (2010).
6. Abbey, D. E. et al. Long-term particulate and other air pollutants and lung
function in nonsmokers. Am. J. Respir. Crit. Care Med. 158, 289–298 (1998).
7. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the
Diagnosis Management and Prevention of COPD. http://www.goldcopd.org/
(2014).
8. Wilk, J. B. et al. Evidence for major genes inﬂuencing pulmonary function in
the NHLBI family heart study. Genet. Epidemiol. 19, 81–94 (2000).
9. Palmer, L. J. et al. Familial aggregation and heritability of adult lung function:
results from the Busselton Health Study. Eur. Respir. J. 17, 696–702 (2001).
10. Hancock, D. B. et al.Meta-analyses of genome-wide association studies identify
multiple loci associated with pulmonary function. Nat. Genet. 42, 45–52 (2010).
11. Loth, D. W. et al. Genome-wide association analysis identiﬁes six new loci
associated with forced vital capacity. Nat. Genet. 46, 669–677 (2014).
12. Repapi, E. et al. Genome-wide association study identiﬁes ﬁve loci associated
with lung function. Nat. Genet. 42, 36–44 (2010).
13. Soler Artigas, M. et al. Genome-wide association and large-scale follow up
identiﬁes 16 new loci inﬂuencing lung function. Nat. Genet. 43, 1082–1090 (2011).
14. Wilk, J. B. et al. A genome-wide association study of pulmonary function
measures in the Framingham Heart Study. PLoS Genet. 5, e1000429 (2009).
15. Maher, B. Personal genomes: the case of the missing heritability. Nature 456,
18–21 (2008).
16. Manolio, T. A. et al. Finding the missing heritability of complex diseases.
Nature 461, 747–753 (2009).
17. Gibson, G. Rare and common variants: twenty arguments. Nat. Rev. Genet. 13,
135–145 (2011).
18. 1000 Genomes Project Consortium. An integrated map of genetic variation
from 1,092 human genomes. Nature 491, 56–65 (2012).
19. Devlin, B. & Roeder, K. Genomic control for association studies. Biometrics 55,
997–1004 (1999).
20. Lamontagne, M. et al. Reﬁning susceptibility loci of chronic obstructive
pulmonary disease with lung eqtls. PLoS ONE 8, e70220 (2013).
21. Westra, H. J. et al. Systematic identiﬁcation of trans eQTLs as putative drivers
of known disease associations. Nat. Genet. 45, 1238–1243 (2013).
22. Rosenbloom, K. R. et al. ENCODE data in the UCSC Genome Browser: year 5
update. Nucleic Acids Res. 41, D56–D63 (2013).
23. Uhlen, M. et al. Towards a knowledge-based Human Protein Atlas. Nat.
Biotechnol. 28, 1248–1250 (2010).
24. GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat.
Genet. 45, 580–585 (2013).
25. Melen, E. et al. Expression analysis of asthma candidate genes during human
and murine lung development. Respir. Res. 12, 86 (2011).
26. Waller-Evans, H. et al. The orphan adhesion-GPCR GPR126 is required for
embryonic development in the mouse. PLoS ONE 5, e14047 (2010).
27. Moriguchi, T. et al. DREG, a developmentally regulated G protein-coupled
receptor containing two conserved proteolytic cleavage sites. Genes Cells 9,
549–560 (2004).
28. Paavola, K. J., Sidik, H., Zuchero, J. B., Eckart, M. & Talbot, W. S. Type IV
collagen is an activating ligand for the adhesion G protein-coupled receptor
GPR126. Sci. Signal. 7, ra76 (2014).
29. Obeidat, M. e et al. GSTCD and INTS12 regulation and expression in the
human lung. PLoS ONE 8, e74630 (2013).
30. Dabovic, B. et al. Function of latent TGFbeta binding protein 4 and ﬁbulin 5 in
elastogenesis and lung development. J. Cell. Physiol. 230, 226–236 (2015).
31. Sterner-Kock, A. et al. Disruption of the gene encoding the latent transforming
growth factor-beta binding protein 4 (LTBP-4) causes abnormal lung
development, cardiomyopathy, and colorectal cancer. Genes Dev. 16,
2264–2273 (2002).
32. Cho, M. H. et al. A genome-wide association study of COPD identiﬁes a
susceptibility locus on chromosome 19q13. Hum. Mol. Genet. 21, 947–957
(2012).
33. Thorgeirsson, T. E. et al. Sequence variants at CHRNB3-CHRNA6 and
CYP2A6 affect smoking behavior. Nat. Genet. 42, 448–453 (2010).
34. Li, J. et al. The anti-proliferative function of the TGF-beta1 signalling pathway
involves the repression of the oncogenic TBX2 by its homologue TBX3. J. Biol.
Chem. 289, 35633–35643 (2014).
35. Follit, J. A. et al. The Golgin GMAP210/TRIP11 anchors IFT20 to the Golgi
complex. PLoS Genet. 4, e1000315 (2008).
36. Kawaguchi, Y. et al. CAG expansions in a novel gene for Machado-Joseph
disease at chromosome 14q32.1. Nat. Genet. 8, 221–228 (1994).
37. Brandsma, C. A. et al. A large lung gene expression study identifying ﬁbulin-5
as a novel player in tissue repair in COPD. Thorax 70, 21–32 (2015).
38. Cho, M. H. et al. Risk loci for chronic obstructive pulmonary disease: a genome-
wide association study and meta-analysis. Lancet. Respir. Med. 2, 214–225 (2014).
39. Groenman, F., Rutter, M., Caniggia, I., Tibboel, D. & Post, M. Hypoxia-
inducible factors in the ﬁrst trimester human lung. J. Histochem. Cytochem. 55,
355–363 (2007).
40. Ovrevik, J. et al. AhR and Arnt differentially regulate NF-kappaB signaling and
chemokine responses in human bronchial epithelial cells. Cell Commun. Signal.
12, 48 (2014).
41. Petrache, I. et al. Ceramide synthases expression and role of ceramide synthase-
2 in the lung: insight from human lung cells and mouse models. PLoS ONE 8,
e62968 (2013).
42. Boyd, A. et al. Cohort Proﬁle: the ‘children of the 90s’—the index offspring of
the Avon Longitudinal Study of Parents and Children. Int. J. Epidemiol. 42,
111–127 (2013).
43. Welter, D. et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait
associations. Nucleic Acids Research 42, D1001–D1006 (2014).
44. Lango Allen, H. et al. Hundreds of variants clustered in genomic loci and
biological pathways affect human height. Nature 467, 832–838 (2010).
45. Lettre, G. et al. Identiﬁcation of ten loci associated with height highlights new
biological pathways in human growth. Nat. Genet. 40, 584–591 (2008).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9658
8 NATURE COMMUNICATIONS | 6:8658 |DOI: 10.1038/ncomms9658 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
46. Berndt, S. I. et al. Genome-wide meta-analysis identiﬁes 11 new loci for
anthropometric traits and provides insights into genetic architecture. Nat.
Genet. 45, 501–512 (2013).
47. Albagha, O. M. et al. Genome-wide association identiﬁes three new
susceptibility loci for Paget’s disease of bone. Nat. Genet. 43, 685–689 (2011).
48. Kemp, J. P. et al. Phenotypic dissection of bone mineral density reveals skeletal
site speciﬁcity and facilitates the identiﬁcation of novel loci in the genetic
regulation of bone mass attainment. PLoS Genet. 10, e1004423 (2014).
49. Pei, Y. F. et al. Meta-analysis of genome-wide association data identiﬁes novel
susceptibility loci for obesity. Hum. Mol. Genet. 23, 820–830 (2014).
50. Macgregor, S. et al. Genome-wide association study identiﬁes a new melanoma
susceptibility locus at 1q21.3. Nat. Genet. 43, 1114–1118 (2011).
51. Porcu, E. et al. A meta-analysis of thyroid-related traits reveals novel loci and
gender-speciﬁc differences in the regulation of thyroid function. PLoS Genet. 9,
e1003266 (2013).
52. Segre`, A. V. et al. Common inherited variation in mitochondrial genes is not
enriched for associations with type 2 diabetes or related glycemic traits. PLoS
Genet. 6, e1001058 (2010).
53. Wood, A. R. et al. Deﬁning the role of common variation in the genomic
and biological architecture of adult human height. Nat. Genet. 46, 1173–1186
(2014).
54. Tada, H. et al. Multiple associated variants increase the heritability explained
for plasma lipids and coronary artery disease. circulation. Cardiovasc. Genet. 7,
583–587 (2014).
55. Wain, L. V. et al. Novel insights into the genetics of smoking behaviour, lung
function, and chronic obstructive pulmonary disease (UK BiLEVE): a genetic
association study in UK Biobank. Lancet Respir. Med. doi: 10.1016/S2213-
2600(15)00283-0 (2015).
56. Soler Artigas, M. et al. Effect of ﬁve genetic variants associated with lung
function on the risk of chronic obstructive lung disease, and their joint effects
on lung function. Am. J. Respir. Crit. Care Med. 184, 786–795 (2011).
57. Castaldi, P. J. et al. The association of genome-wide signiﬁcant spirometric loci
with chronic obstructive pulmonary disease susceptibility. Am. J. Respir. Cell
Mol. Biol. 45, 1147–1153 (2011).
58. Pillai, S. G. et al. A genome-wide association study in chronic obstructive
pulmonary disease (COPD): identiﬁcation of two major susceptibility loci. PLoS
Genet. 5, e1000421 (2009).
59. Cho, M. H. et al. Variants in FAM13A are associated with chronic obstructive
pulmonary disease. Nat. Genet. 42, 200–202 (2010).
60. Wilk, J. B. et al. Genome-wide association studies identify CHRNA5/3 and
HTR4 in the development of airﬂow obstruction. Am. J. Respir. Crit. Care Med.
186, 622–632 (2012).
61. Li, Y. & Abecasis, G. R. Mach 1.0: rapid haplotype construction and missing
genotype inference. Am. J. Hum. Genet. S79, 2290 (2006).
62. Howie, B., Fuchsberger, C., Stephens, M., Marchini, J. & Abecasis, G. R. Fast
and accurate genotype imputation in genome-wide association studies through
pre-phasing. Nat. Genet. 44, 955–959 (2012).
63. Howie, B. N., Donnelly, P. & Marchini, J. A ﬂexible and accurate genotype
imputation method for the next generation of genome-wide association studies.
PLoS Genet. 5, e1000529 (2009).
64. Fuchsberger, C., Taliun, D., Pramstaller, P. P., Pattaro, C. & consortium, C. K
GWAtoolbox: an R package for fast quality control and handling of genome-
wide association studies meta-analysis data. Bioinformatics 28, 444–445 (2012).
65. Yang, J. et al. Conditional and joint multiple-SNP analysis of GWAS summary
statistics identiﬁes additional variants inﬂuencing complex traits. Nat. Genet.
44, S361–S363 (2012).
66. Kumar, P., Henikoff, S. & Ng, P. C. Predicting the effects of coding non-
synonymous variants on protein function using the SIFT algorithm. Nat.
Protoc. 4, 1073–1081 (2009).
67. Adzhubei, I. A. et al. A method and server for predicting damaging missense
mutations. Nat. Methods 7, 248–249 (2010).
68. Kircher, M. et al. A general framework for estimating the relative pathogenicity
of human genetic variants. Nat. Genet. 46, 310–315 (2014).
69. Ritchie, G. R., Dunham, I., Zeggini, E. & Flicek, P. Functional annotation of
noncoding sequence variants. Nat. Methods 11, 294–296 (2014).
70. Steiling, K. et al. A dynamic bronchial airway gene expression signature of
chronic obstructive pulmonary disease and lung function impairment. Am. .
Respir. Crit. Care Med. 187, 933–942 (2013).
Acknowledgements
The research undertaken by M.D.T., M.S.A. and L.V.W. was partly funded by the
National Institute for Health Research (NIHR). The views expressed are those of the
author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
M.D.T. holds a Medical Research Council Senior Clinical Fellowship (G0902313). This
research used the ALICE High Performance Computing Facility at the University of
Leicester. The Universities of Leicester and Nottingham acknowledge receipt of a
Collaborative Research and Development grant from the Healthcare and Bioscience iNet,
a project funded by the East Midlands Development Agency, part-ﬁnanced by the
European Regional Development Fund and delivered by Medilink East Midlands. I.P.H.
holds a Medical Research Council programme grant (G1000861). We acknowledge the
use of phenotype and genotype data from the British 1958 Birth Cohort DNA collection,
funded by the Medical Research Council grant G0000934 and the Wellcome Trust grant
068545/Z/02 (http://www.b58cgene.sgul.ac.uk/). Genotyping for the B58C-WTCCC
subset was funded by the Wellcome Trust grant 076113/B/04/Z. The B58C-T1DGC
genotyping utilized resources provided by the Type 1 Diabetes Genetics Consortium, a
collaborative clinical study sponsored by the National Institute of Diabetes and Digestive
and Kidney Diseases, National Institute of Allergy and Infectious Diseases, National
Human Genome Research Institute, National Institute of Child Health and Human
Development and Juvenile Diabetes Research Foundation International and supported by
U01 DK062418. B58C-T1DGC GWAS data were deposited by the Diabetes and
Inﬂammation Laboratory, Cambridge Institute for Medical Research (CIMR), University
of Cambridge, which is funded by Juvenile Diabetes Research Foundation International,
the Wellcome Trust and the National Institute for Health Research Cambridge
Biomedical Research Centre; the CIMR is in receipt of a Wellcome Trust Strategic Award
(079895). The B58C-GABRIEL genotyping was supported by a contract from the
European Commission Framework Programme 6 (018996) and grants from the French
Ministry of Research. The Busselton Health Study (BHS) acknowledges the generous
support for the 1994/5 follow-up study from Healthway, Western Australia and the
numerous Busselton community volunteers who assisted with data collection and the
study participants from the Shire of Busselton. The BHS is supported by The Great Wine
Estates of the Margaret River region of Western Australia. GWAS genotyping was
supported by a research collaboration with Pﬁzer. The CROATIA study was supported
through grants from the Medical Research Council UK, the Ministry of Science,
Education and Sport in the Republic of Croatia (number 216-1080315-0302), Croatian
Science Foundation (grant number 8875) and the European Union framework program 6
EUROSPAN project (contract no. LSHG-CT-2006-018947). SNP genotyping for
CROATIA-Vis was performed by the Wellcome Trust Clinical Research Facility
(WTCRF) at the Western General Hospital, Edinburgh, UK. CROATIA-Korcula was
genotyped by Helmholz Zentrum Mu¨nchen, GmbH, Neuherberg, Germany and
CROATIA-Split by AROS Applied Biotechnology, Aarhus, Denmark. We would like to
acknowledge the invaluable contributions of the recruitment teams in Croatia (including
those from the Institute of Anthropological Research in Zagreb and the Croatian Centre
for Global Health at the University of Split), the administrative teams in Croatia and
Edinburgh and the people of Korcula, Vis and Split. The EPIC Norfolk Study is funded
by program grants from the Medical Research Council UK and Cancer Research UK, and
by additional support from the European Union, Stroke Association, British Heart
Foundation, Department of Health, Food Standards Agency and the Wellcome Trust.
GS:SFHS is funded by the Scottish Executive Health Department, Chief Scientist Ofﬁce,
grant number CZD/16/6. Exome array genotyping for GS:SFHS was funded by the
Medical Research Council UK and performed at the Wellcome Trust Clinical Research
Facility Genetics Core at Western General Hospital, Edinburgh, UK. We acknowledge
the invaluable contributions of the families who took part in the Generation Scotland:
Scottish Family Health Study, the general practitioners and Scottish School of Primary
Care for their help in recruiting them and the whole Generation Scotland team, which
includes academic researchers, IT staff, laboratory technicians, statisticians and research
managers. This study was ﬁnancially supported by the Medical Research Fund of the
Tampere University Hospital. S.R. was supported by the Academy of Finland (251217
and 255847), Center of Excellence in Complex Disease Genetics, EU FP7 projects
ENGAGE (201413) and BioSHaRE (261433), the Finnish Foundation for Cardiovascular
Research, Biocentrum Helsinki and the Sigrid Juselius Foundation. The KORA authors
acknowledge all members of ﬁeld staffs who were involved in the planning and con-
duction of the KORA Augsburg studies, as well as all KORA study participants. The
KORA research platform (KORA, Cooperative Health Research in the Region of
Augsburg) was initiated and ﬁnanced by the Helmholtz Zentrum Mu¨nchen—German
Research Center for Environmental Health, which is funded by the German Federal
Ministry of Education and Research and by the State of Bavaria. The KORA-Age project
was ﬁnanced by the German Federal Ministry of Education and Research (BMBF FKZ
01ET0713 and 01ET1003A) as part of the ‘Health in old age’ program. Furthermore,
KORA research was supported within the Munich Center of Health Sciences (MC
Health), Ludwig-Maximilians-Universita¨t, as part of LMUinnovativ. Further support was
provided by the Competence Network ASCONET, subnetwork COSYCONET (FKZ
01GI0882). We thank the cohort participants who contributed to this study. Genotyping
was supported by the UK’s Biotechnology and Biological Sciences Research Council
(BBSRC) (ref. BB/F019394/1). Phenotype collection was supported by Research Into
Ageing (continues as part of Age UK’s The Disconnected Mind project). The work was
undertaken by The University of Edinburgh Centre for Cognitive Ageing and Cognitive
Epidemiology, part of the cross council Lifelong Health and Wellbeing Initiative (MR/
K026992/1). Funding from the BBSRC and Medical Research Council (MRC) is grate-
fully acknowledged. We thank the late Professor Paula Rantakallio (launch of
NFBC1966), and Ms Outi Tornwall and Ms MinttuJussila (DNA biobanking).
NFBC1966 received ﬁnancial support from the Academy of Finland (project grants
104781, 120315, 129269, 1114194 and 24300796), University Hospital Oulu, Biocenter,
University of Oulu, Finland (75617), NHLBI grant 5R01HL087679-02 through the
STAMPEED program (1RL1MH083268-01), NIH/NIMH (5R01MH63706:02), EU FP7
(HEALTH-F4-2007-201413), EU FP8 (277849) and Medical Research Council, UK
(G0500539, G1002319 and G0600705). U.G. acknowledges Swedish Medical Research
Council (K2007-66X-20270-01-3, 2012-2884), Foundation for Strategic Research (SSF)
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9658 ARTICLE
NATURE COMMUNICATIONS | 6:8658 | DOI: 10.1038/ncomms9658 | www.nature.com/naturecommunications 9
& 2015 Macmillan Publishers Limited. All rights reserved.
and European Commission FP6 STRP (LSHG-CT-2006-01947). Å.J. acknowledges
Swedish Society for Medical Research. The ORCADES study was funded by the Chief
Scientist Ofﬁce of the Scottish Government, the Royal Society and the MRC Human
Genetics Unit. DNA extraction was performed at the Wellcome Trust Clinical Research
Facility in Edinburgh. Genotyping was funded by the European Union Framework
Programme 6 EUROSPAN project. Study directorate: NM Probst-Hensch (PI; e/g);
T. Rochat (p), C. Schindler (s), N. Ku¨nzli (e/exp), J.M. Gaspoz (c) Scientiﬁc team:
J.C. Barthe´le´my (c), W. Berger (g), R. Bettschart (p), A. Bircher (a), C. Brombach (n),
P.O. Bridevaux (p), L. Burdet (p), Felber Dietrich D. (e), M. Frey (p), U. Frey (pd),
M.W. Gerbase (p), D. Gold (e), E. de Groot (c), W. Karrer (p), F. Kronenberg (g),
B. Martin (pa), A. Mehta (e), D. Miedinger (o), M. Pons (p), F. Roche (c), T. Rothe (p),
P. Schmid-Grendelmeyer (a), D. Stolz (p), A. Schmidt-Trucksa¨ss (pa), J. Schwartz (e),
A. Turk (p), A. von Eckardstein (cc) and E. Zemp Stutz (e). Scientiﬁc team at coordi-
nating centers: M. Adam (e), I. Aguilera (exp), S. Brunner (s), D. Carballo (c), S. Caviezel
(pa), I. Curjuric (e), A. Di Pascale (s), J. Dratva (e), R. Ducret (s), E. Dupuis Lozeron (s),
M. Eeftens (exp), I. Eze (e), E. Fischer (g), M. Foraster (e), M. Germond (s), L. Grize (s),
S. Hansen (e), A. Hensel (s), M. Imboden (g), A. Ineichen (exp), A. Jeong (g),
D. Keidel (s), A. Kumar (g), N. Maire (s), A. Mehta (e), R. Meier (exp), E. Schaffner (s),
T. Schikowski (e) and M. Tsai (exp); (a) allergology, (c) cardiology, (cc) clinical
chemistry, (e) epidemiology, (exp) exposure, (g) genetic and molecular biology, (m)
meteorology, (n) nutrition, (o) occupational health, (p) pneumology, (pa) physical
activity, (pd) pediatrics and (s) statistic. The study could not have been done without the
help of the study participants, technical and administrative support and the medical
teams and ﬁeld workers at the local study sites. Local ﬁeld workers: Aarau: S. Brun,
G. Giger, M. Sperisen and M. Stahel; Basel: C. Bu¨rli, C. Dahler, N. Oertli, I. Harreh,
F. Karrer, G. Novicic and N. Wyttenbacher; Davos: A. Saner, P. Senn and R. Winzeler;
Geneva: F. Bonﬁls, B. Blicharz, C. Landolt and J. Rochat; Lugano: S. Boccia, E. Gehrig,
M.T. Mandia, G. Solari and B. Viscardi; Montana: A.P. Bieri, C. Darioly and M. Maire;
Payerne: F. Ding and P. Danieli A. Vonnez; Wald: D. Bodmer, E. Hochstrasser, R. Kunz,
C. Meier, J. Rakic, U. Schafroth and A. Walder. Administrative staff: N. Bauer Ott,
C. Gabriel, R. Gutknecht. Funding: The Swiss National Science Foundation (grants nos
33CS30-148470/1, 33CSCO-134276/1, 33CSCO-108796, 3247BO-104283, 3247BO-
104288, 3247BO-104284, 3247-065896, 3100-059302, 3200-052720, 3200-042532,
4026-028099, PMPDP3_129021/1 and PMPDP3_141671/1), the Federal Ofﬁce for the
Environment, the Federal Ofﬁce of Public Health, the Federal Ofﬁce of Roads and
Transport, the Canton’s Government of Aargau, Basel-Stadt, Basel-Land, Geneva,
Luzern, Ticino, Valais and Zu¨rich, the Swiss Lung League, the Canton’s Lung League of
Basel-Stadt/ Basel Landschaft, Geneva, Ticino, Valais, Graubu¨nden and Zurich, Stiftung
ehemals Bu¨ndner Heilsta¨tten, SUVA, Freiwillige Akademische Gesellschaft, UBS Wealth
Foundation, Talecris Biotherapeutics GmbH, Abbott Diagnostics, European Commission
018996 (GABRIEL), and Wellcome Trust WT 084703MA. SHIP is part of the
Community Medicine Research net of the University of Greifswald, Germany, which is
funded by the Federal Ministry of Education and Research, the Ministry of Cultural
Affairs as well as the Social Ministry of the Federal State of Mecklenburg-West
Pomerania, and the network ‘Greifswald Approach to Individualized Medicine
(GANI_MED)’ funded by the Federal Ministry of Education and Research, and the
German Asthma and COPD Network (COSYCONET) (grant nos 01ZZ9603, 01ZZ0103,
01ZZ0403, 03IS2061A and BMBF 01GI0883). Genome-wide data have been supported
by the Federal Ministry of Education and Research and a joint grant from Siemens
Healthcare, Erlangen, Germany and the Federal State of Mecklenburg-West Pomerania
(grant no. 03ZIK012). The University of Greifswald is a member of the ‘Center of
Knowledge Interchange’ program of the Siemens AG and the Cache´ Campus program of
the InterSystems GmbH. We acknowledge the Academy of Finland (126925, 121584 and
124282), Academy of Finland (Eye) (134309), Academy of Finland (Salve) (129378),
Academy of Finland (Gendi) (117787), Academy of Finland (Skidi) (41071), Social
Insurance Institution of Finland,Tampere University Hospital Medical Funds (X51001
for T.L.), Kuopio University Hospital Medical Funds, Turku University Hospital Medical
Funds, Juho Vainio Foundation, Paavo Nurmi Foundation, Finnish Foundation of
Cardiovascular Research (T.L.), Finnish Cultural Foundation, Tuberculosis Foundation
(T.L.), Emil Aaltonen Foundation (T.L.) and Yrjo¨ Jahnsson Foundation (T.L.). We are
extremely grateful to all the families who took part in the study, the midwives for their
help in recruiting them and the whole ALSPAC team, which includes interviewers,
computer and laboratory technicians, clerical workers, research scientists, volunteers,
managers, receptionists and nurses. The UK Medical Research Council and the Well-
come Trust (grant ref: 092731) and the University of Bristol provide core support for
ALSPAC. This publication is the work of the authors and D.M.E. will serve as guarantor
for the contents of this paper. This work was funded by a Medical Research Council
(MRC) strategic award to M.D.T., I.P.H., D.P.S. and L.V.W. (MC_PC_12010). This
research has been conducted using the UK Biobank Resource. M.D.T. has been sup-
ported by MRC fellowships G0501942 and G0902313. I.P.H. is supported by an MRC
programme grant (G1000861). J.M. is funded by an ERC Consolidator Grant (617306).
This article presents independent research funded partially by the NIHR. The views
expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or
the Department of Health. We would like to acknowledge all members of the UK
Biobank Array Design Group. The views expressed are those of the author(s) and not
necessarily those of the NHS, the NIHR or the Department of Health. Peter Donnelly
(chair) (University of Oxford), Jeff Barrett (Wellcome Trust Sanger Institute), Jose Bras
(University College London), Adam Butterworth (University of Cambridge), Richard
Durbin (Wellcome Trust Sanger Institute), Paul Elliott (Imperial College London), Ian
Hall (University of Nottingham), John Hardy (University College London), Mark
McCarthy (University of Oxford), Gil McVean (University of Oxford), Tim Peakman
(UK Biobank), Nazneen Rahman (The Institute of Cancer Research), Nilesh Samani
(University of Leicester), Martin Tobin (University of Leicester), Hugh Watkins (Uni-
versity of Oxford). We acknowledge EU funding (GABRIEL Grant Number: 018996,
ECRHS II Coordination Number: QLK4-CT-1999-01237). A.P.M. acknowledges the
Wellcome Trust (WT098017,WT064890 and WT090532). The PIVUS study acknowl-
edges The Swedish Foundation for Strategic Research (ICA08-0047), The Swedish
Research Council (2012-1397), The Swedish Heart-Lung Foundation (20120197), The
Swedish Society of Medicine and Uppsala University. The computations were performed
on resources provided by SNIC through Uppsala Multidisciplinary Center for Advanced
Computational Science (UPPMAX) under Project p2013056. A.P.M. is a Wellcome Trust
Senior Research Fellow in Basic Biomedical Science (grant number WT098017). This
cohort received funding from the Wellcome Trust; the European Community’s Seventh
Framework Programme (FP7/2007-13); US National Institutes of Health/National Eye
Institute (1RO1EY018246); NIH Center for Inherited Disease Research; the NIHR-
funded BioResource, Clinical Research Facility and Biomedical Research Centre based at
Guy’s and St Thomas’ NHS Foundation Trust in partnership with King’s College Lon-
don. We thank the research staff at the Respiratory Health Network Tissue Bank of the
FRQS for collecting lung specimens for the lung eQTL study at the Laval University. The
Lung Tissue eQTL study was funded by Merck Research Laboratories. M.O. is a Post-
doctoral Fellow of the Michael Smith Foundation for Health Research and the Canadian
Institute for Health Research Integrated and Mentored Pulmonary and Cardiovascular
Training program (IMPACT). Y.B. is the recipient of a Junior 2 Research Scholar award
from the Fonds de recherche Que´bec—Sante´ (FRQS).
Author contributions
I.P.H., S.M., N.S., M.S.A., D.P.S., M.D.T. and L.V.W. contributed to analysis. I.P.H,
A.K.K., E.M., S.M., I.N., I.S., M.S.A., M.D.T. and L.V.W. carried out bioinformatics and
functional assessment. I.P.H., S.M., M.S.A., D.P.S., M.D.T. and L.V.W. wrote the
manuscript. Project conception, design and management: Stage 1—B58C: D.P.S.;
CROATIA-Korcula: C.H.; CROATIA-Split: I.K., O.P., V.V. and T.Z.; CROATIA-Vis: I.R.
and A.F.W.; EPIC: J.H.Z., R.A.S. and N.J.W.; GS:SFHS: L.H., S.P. and G.S.; H2000:
M. Helio¨vaara and M.K.; KORA F4: J. Heinrich; KORA S3: C.G., S.K. and H.S.; LBC1936:
I.J.D. and J.M.S.; NFBC1966: M.-R.J.; NSPHS: U.G.; ORCADES: H.C., S.H.W. and J.F.W.;
SAPALDIA: N.M.P.-H.; SHIP: S.G., B.K. and H.V.; YFS: T.L. and O.T.R. Stage 2—
ECRHS: J. Heinrich and D.L.J.; PIVUS: L.L.; TwinsUK: T.D.S. Phenotype collection and
data management: Stage 1—B58C: W.L.M. and D.P.S.; BHS1&2: J.B., J. Hui, A.L.J.
and A.W.M.; CROATIA-Korcula: C.H., J.E.H. and P.N.; CROATIA-Split: I.K., O.P., V.V.
and T.Z.; CROATIA-Vis: J.M.; EPIC: J.H.Z.; GS:SFHS: L.H., S.P., G.S. and H.T.; H2000:
M. Helio¨vaara, M.K., S.R. and I. Surakka; KORA F4: H.G. and J.S.R.; KORA S3: C.G.,
S.K., R.R. and H.S.; LBC1936: I.J.D., S.E.H., L.M.L. and J.M.S.; NFBC1966: A.C.A.,
A.-L.H. and M.-R.J.; NSPHS: S.E. and A.J.; ORCADES: H.C., S.H.W. and J.F.W.;
SAPALDIA: M.I., A.K. and N.M.P.-H.; SHIP: S.G., B.S., A.T. and H.V.; YFS: N.H.-K.,
T.L. and O.T.R. Stage 2—ALSPAC: R.G., J. Henderson and J.P.K.; ECRHS: J.R.G., J.
Heinrich and D.L.J.; PIVUS: E.I., L.L., A.M. and A.P.M.; TwinsUK: C.J.H., P.G.H., T.D.S.
and A.V.; Lung eQTL study: Y.B., C.-A.B., D.C.N. and D.D.S. Data analysis: Stage
1—B58C: D.P.S.; CROATIA-Korcula: J.E.H. and P.N.; CROATIA-Vis: J.M.; EPIC: J.H.Z.;
H2000: M.K., S.R. and I. Surakka; KORA F4: E.A. and J.S.R.; KORA S3: R.R.; LBC1936:
L.M.L.; NFBC1966: A.C.A., M. Horikoshi and M.-R.J.; NSPHS: S.E.; ORCADES: P.K.J.;
SAPALDIA: M.I., A.K. and N.M.P.-H.; SHIP: A.T.; YFS: L.-P.L. Stage 2—ALSPAC:
D.M.E.; ECRHS: C.F.; PIVUS: A.M. and A.P.M.; TwinsUK: P.G.H; Lung eQTL
study: M.O.
Additional information
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing ﬁnancial interests: The authors declare no competing ﬁnancial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
How to cite this article: Artigas, M. S. et al. Sixteen new lung function signals identiﬁed
through 1000 Genomes Project reference panel imputation. Nat. Commun. 6:8658
doi: 10.1038/ncomms9658 (2015).
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise
in the credit line; if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to reproduce the material.
To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9658
10 NATURE COMMUNICATIONS | 6:8658 |DOI: 10.1038/ncomms9658 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
Marı´a Soler Artigas1,*, Louise V. Wain1,*, Suzanne Miller2,*, Abdul Kader Kheirallah2, Jennifer E. Huffman3,
Ioanna Ntalla1, Nick Shrine1, Ma’en Obeidat4, Holly Trochet3,5, Wendy L. McArdle6, Alexessander Couto Alves7,
Jennie Hui8,9,10,11, Jing Hua Zhao12, Peter K. Joshi13, Alexander Teumer14,15, Eva Albrecht16, Medea Imboden17,18,
Rajesh Rawal16,19,20, Lorna M. Lopez21,22, Jonathan Marten3, Stefan Enroth23, Ida Surakka24,25,
Ozren Polasek13,26, Leo-Pekka Lyytika¨inen27,28, Raquel Granell6, Pirro G. Hysi29, Claudia Flexeder30,
Anubha Mahajan31, John Beilby8,9,32, Yohan Bosse´33, Corry-Anke Brandsma34, Harry Campbell13,
Christian Gieger16,19,20, Sven Gla¨ser35, Juan R. Gonza´lez36,37,38, Harald Grallert19, Chris J. Hammond29,
Sarah E. Harris21,39, Anna-Liisa Hartikainen40, Markku Helio¨vaara25, John Henderson6, Lynne Hocking5,41,
Momoko Horikoshi31,42, Nina Hutri-Ka¨ho¨nen43,44, Erik Ingelsson31,45,46, Åsa Johansson23,47, John P.
Kemp6,48,49, Ivana Kolcic26, Ashish Kumar17,18,31,50, Lars Lind51, Erik Mele´n52, Arthur W. Musk8,53,54, Pau
Navarro3, David C. Nickle55, Sandosh Padmanabhan5,56, Olli T. Raitakari57,58, Janina S. Ried16,
Samuli Ripatti24,59,60, Holger Schulz30,61, Robert A. Scott12, Don D. Sin4,62, John M. Starr21,63, UK BiLEVEw,
Ana Vin˜uela29, Henry Vo¨lzke14, Sarah H. Wild13, Alan F. Wright3, Tatijana Zemunik64, Deborah L. Jarvis65,66,
Tim D. Spector29, David M. Evans6,48,49, Terho Lehtima¨ki27,28, Veronique Vitart3, Mika Ka¨ho¨nen67,
Ulf Gyllensten23, Igor Rudan13,68, Ian J. Deary21,22, Stefan Karrasch30,69,70, Nicole M. Probst-Hensch17,18,
Joachim Heinrich30,61,71, Beate Stubbe35, James F. Wilson3,13, Nicholas J. Wareham12, Alan L. James8,72,54,
Andrew P. Morris31,73,74, Marjo-Riitta Jarvelin7,75,76,77, Caroline Hayward5, Ian Sayers2,
David P. Strachan78,*, Ian P. Hall2,* & Martin D. Tobin1,79,*
1 Genetic Epidemiology Group, Department of Health Sciences, University of Leicester, Leicester LE1 7RH, UK. 2 Division of Respiratory Medicine, Queen’s
Medical Centre, University of Nottingham, Nottingham NG7 2RD, UK. 3MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine,
University of Edinburgh, Edinburgh, Scotland EH8 9AD, UK. 4 University of British Columbia Centre for Heart Lung Innovation, St Paul’s Hospital, Vancouver,
British Columbia, Canada V6Z 1Y6. 5 Generation Scotland, A Collaboration between the University Medical Schools and NHS, Aberdeen, Dundee, Edinburgh,
Glasgow EH4 2XU, UK. 6 School of Social and Community Medicine, University of Bristol, Bristol BS8 1TH, UK. 7 Department of Epidemiology and
Biostatistics, MRC -PHE Centre for Environment & Health, School of Public Health, Imperial College London, London SW7 2AZ, UK. 8 Busselton Population
Medical Research Institute, Busselton, Western Australia 6280, Australia. 9 PathWest Laboratory Medicine WA, Sir Charles Gairdner Hospital, Western
Australia 6009, Australia. 10 School of Population Health, The University of Western Australia, Western Australia 6009, Australia. 11 School of Pathology and
Laboratory Medicine, The University of Western Australia, Western Australia 6009, Australia. 12MRC Epidemiology Unit, University of Cambridge School of
Clinical Medicine, Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge CB2 0SL, UK. 13 Usher Institute of Population Health Sciences
and Informatics, University of Edinburgh, Teviot Place, Edinburgh EH8 9AD, Scotland, UK. 14 University Medicine Greifswald, Community Medicine, SHIP—
Clinical Epidemiological Research, Greifswald 17489, Germany. 15 Department for Genetics and Functional Genomics, Interfaculty Institute for Genetics and
Functional Genomics, University Medicine Greifswald, Greifswald 17489, Germany. 16 Institute of Genetic Epidemiology, Helmholtz Zentrum Mu¨nchen
German Research Center for Environmental Health, Neuherberg D-85764, Germany. 17 Swiss Tropical and Public Health Institute, Basel 4051, Switzerland.
18 University of Basel, Basel 4001, Switzerland. 19 Research Unit of Molecular Epidemiology, Helmholtz Zentrum Mu¨nchen, German Research Center for
Environmental Health, Neuherberg D-85764, Germany. 20 Institute of Epidemiology II, Helmholtz Zentrum Mu¨nchen German Research Center for
Environmental Health, Neuherberg D-85764, Germany. 21 Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh EH8
9AD, UK. 22 Department of Psychology, University of Edinburgh, Edinburgh EH8 9AD, UK. 23 Department of Immunology, Genetics, and Pathology,
Biomedical Center, SciLifeLab Uppsala, Uppsala University, Uppsala 751 23, Sweden. 24 Institute for Molecular Medicine Finland (FIMM), University of
Helsinki, Helsinki FI-00014, Finland. 25 The National Institute for Health and Welfare (THL), Helsinki FI-00271, Finland. 26 Department of Public Health,
Faculty of Medicine, University of Split, Split 21000, Croatia. 27Department of Clinical Chemistry, Fimlab Laboratories, Tampere FI-33101, Finland.
28Department of Clinical Chemistry, University of Tampere School of Medicine, Tampere FI-33520, Finland. 29 KCL Department of Twins Research and
Genetic Epidemiology, King’s College London, London WC2R 2LS, UK. 30 Institute of Epidemiology I, Helmholtz Zentrum Mu¨nchen, German Research Center
for Environmental Health, Neuherberg D-85764, Germany. 31Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK.
32 School of Pathology and Laboratory Medicine, The University of Western Australia, Western Australia 6009, Australia. 33 Department of Molecular
Medicine, Institut Universitaire de Cardiologie et de Pneumologie de Que´bec, Laval University, Que´bec, Canada G1V 0A6. 34Department of Pathology and
Medical Biology, University of Groningen, University Medical Center Groningen, Groningen 9700, The Netherlands. 35 Department of Internal Medicine B,
Pneumology, Cardiology, Intensive Care, Weaning, Field of Research: Pneumological Epidemiology, University Medicine Greifswald, Greifswald 17489,
Germany. 36 Centre for Research in Environmental Epidemiology (CREAL), Barcelona E-08003, Spain. 37 CIBER Epidemiologı´a y Salud Pu´blica (CIBERESP),
Madrid 28029, Spain. 38 Pompeu Fabra University (UPF), Barcelona 08002, Catalonia, Spain. 39 Centre for Genomic and Experimental Medicine, University of
Edinburgh, Edinburgh EH8 9AD, UK. 40Department of Obstetrics and Gynecology of Oulu University Hospital ,MRC of Oulu University, Oulu 90220, Finland.
41 Division of Applied Health Sciences, University of Aberdeen, Aberdeen, Scotland AB24 3FX, UK. 42Oxford Centre for Diabetes, Endocrinology and
Metabolism, University of Oxford, Oxford OX1 2JD, UK. 43 Department of Pediatrics, Tampere University Hospital, Tampere 33521, Finland. 44Department of
Pediatrics, University of Tampere School of Medicine, Tampere FI-33520, Finland. 45 Department of Medical Sciences, Molecular Epidemiology and Science
for Life Laboratory, Uppsala University, Uppsala 751 23, Sweden. 46Department of Medicine, Division of Cardiovascular Medicine, Stanford University School
of Medicine, Stanford, California 94305, USA. 47 Uppsala Clinical Research Centre, Uppsala University, Uppsala 751 23, Sweden. 48Diamantina Institute,
Translational Research Institute, University of Queensland, Brisbane, Queensland QLD 4072, Australia. 49MRC Integrative Epidemiology Unit, Bristol BS8
1TH, UK. 50 Institute of Environmental Medicine, Karolinska Institutet, Stockholm SE-171 7, Sweden. 51 Department of Medical Sciences, Uppsala University,
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9658 ARTICLE
NATURE COMMUNICATIONS | 6:8658 | DOI: 10.1038/ncomms9658 | www.nature.com/naturecommunications 11
& 2015 Macmillan Publishers Limited. All rights reserved.
Uppsala 751 23, Sweden. 52 Institute of Environmental Medicine, Karolinska Institutet and Sachs’ Children’s Hospital, Stockholm SE-171 7, Sweden.
53 Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Western Australia 6009, Australia. 54 School of Medicine and Pharmacology, The
University of Western Australia, Western Australia 6009, Australia. 55 Genetics and Pharmacogenomics, Merck Research Labs, Boston, Massachusetts
02115, USA. 56 Division of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow G12 8TA, Scotland, UK. 57 Department of Clinical Physiology
and Nuclear Medicine, Turku University Hospital, Turku 20520, Finland. 58 Research Centre of Applied and Preventive Cardiovascular Medicine, University of
Turku, Turku 20014, Finland. 59Department of Public Health, University of Helsinki, Helsinki FI-00014, Finland. 60Department of Human Genomics,
Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK. 61 Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center
for Lung Research, Munich 85764, Germany. 62 Respiratory Division, University of British Columbia, Vancouver, British Columbia, Canada V6T 1Z4.
63 Alzheimer Scotland Research Centre, University of Edinburgh, Edinburgh EH8 9AD, UK. 64Department of Medical Biology, Faculty of Medicine, University
of Split, Split 21000, Croatia. 65 Respiratory Epidemiology and Public Health, Imperial College London, London SW7 2AZ, UK. 66MRC Health Protection
Agency (HPA) Centre for Environment and Health, Imperial College London, London SW7 2AZ, UK. 67Department of Clinical Physiology, University of
Tampere and Tampere University Hospital, Tampere 33521, Finland. 68 Centre for Population Health Sciences, Medical School, University of Edinburgh,
Edinburgh EH8 9AD, Scotland, UK. 69 Institute of General Practice, University Hospital Klinikum rechts der Isar, Technische Universita¨t Mu¨nchen, Munich D -
81675, Germany. 70 Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Ludwig-Maximilians-Universita¨t, Munich 80539,
Germany. 71 University Hospital Munich, Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Ludwig-Maximilian University
Munich, Munich 80539, Germany. 72 Department of Pulmonary Physiology and Sleep Medicine, Sir Charles Gairdner Hospital, Western Australia 6009,
Australia. 73 Department of Biostatistics, University of Liverpool, Liverpool L69 7ZX, UK. 74 Estonian Genome Centre, University of Tartu, Tartu 50090,
Estonia. 75 Center for Life Course Epidemiology, Faculty of Medicine, P.O.Box 5000, FI-90014 University of Oulu, Oulu FI-01051, Finland. 76 Biocenter Oulu,
P.O.Box 5000, Aapistie 5A, FI-90014 University of Oulu, Oulu FI-01051, Finland. 77 Unit of Primary Care, Oulu University Hospital, Kajaanintie 50, P.O.Box 20,
FI-90220 Oulu, 90029 OYS, Finland. 78 Population Health Research Institute, St George’s, University of London, Cranmer Terrace, London WC1B 5DN, UK.
79National Institute for Health Research (NIHR) Leicester Respiratory Biomedical Research Unit, Glenﬁeld Hospital, Leicester LE3 9QP, UK. * These authors
contributed equally to this work. wA full list of consortium members appears at the end of the paper.
UK BiLEVE
Panos Deloukas80, Anna L. Hansell81, Richard Hubbard82, Victoria E Jackson83, Jonathan Marchini84,
Ian Pavord85, Neil C. Thomson86, and Eleftheria Zeggini87
80William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University London, London E1 4NS, UK.
81UK Small Area Health Statistics Unit, MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, London SW7 2AZ,
UK. 82School of Medicine, University of Nottingham, Nottingham NG7 2RD, UK. 83Department of Health Sciences, University of Leicester, Leicester LE1 7RH,
UK. 84Department of Statistics, University of Oxford, Oxford OX1 2JD, UK. 85Respiratory Medicine, University of Oxford, Oxford OX1 2JD, UK.
86Institute of Infection, Immunity & Inﬂammation, University of Glasgow, Glasgow G12 8TA, UK. 87Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire
CB10 1SA, UK.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9658
12 NATURE COMMUNICATIONS | 6:8658 |DOI: 10.1038/ncomms9658 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
